PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.76%
Both companies show declining cash positions (-19.76% vs AXSM's -23.58%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.76%
Cash + STI yoy 0.75-0.9x AXSM's -23.58%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.43%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-20.12%
0.75-0.9x AXSM's -22.39%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
13.37%
Below half AXSM's -2.93%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.42%
≥ 1.5x AXSM's 0.21%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
0.75-0.9x AXSM's -22.24%. Bill Ackman questions if competitor invests more aggressively for growth.
-6.57%
Less than half of AXSM's -18.05%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AXSM's 100.62%. David Dodd sees fewer expansions in other current obligations.
-17.63%
Less than half of AXSM's 1.11%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.63%
Above 1.5x AXSM's -4.15%. Michael Burry sees a potential leverage warning sign.
0.13%
Less than half of AXSM's 2.74%. David Dodd sees fewer share issuances vs. competitor.
-2.90%
Below half AXSM's -10.17%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.63%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
Below half AXSM's -812.46%. Michael Burry sees potential underperformance in building shareholder capital.
-19.74%
Below half AXSM's -368.28%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.76%
50-75% of AXSM's 31.82%. Bruce Berkowitz notes comparatively lower net debt expansion.